Company intelligence / Profile preview

Linnaeus Therapeutics

Haddonfield, New Jersey, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

LNS8801, the lead candidate, is an orally bioavailable small molecule GPER agonist. In phase 1/2 trials, it has shown safety, tolerability, target engagement (GPER activation, c-Myc depletion), and preliminary clinical benefit in advanced cancer, particularly metastatic cutaneous melanoma. Orphan drug designation has been granted. A randomized pivotal trial in melanoma progressing after checkpoint inhibitors is planned.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

lns-8801

1 more asset in the full pipeline.

Request access →

Partnerships

Penn Center for Innovation UPstart (University of Pennsylvania)

Beyond the preview

Go deeper on Linnaeus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Linnaeus Therapeutics.

Explore the full profile